{"id":148104,"date":"2022-10-13T17:23:26","date_gmt":"2022-10-13T22:23:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/10\/vincov-19-an-antidote-and-a-cure-against-covid-19-completes-phase-2-clinical-trials"},"modified":"2022-10-13T17:23:26","modified_gmt":"2022-10-13T22:23:26","slug":"vincov-19-an-antidote-and-a-cure-against-covid-19-completes-phase-2-clinical-trials","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/10\/vincov-19-an-antidote-and-a-cure-against-covid-19-completes-phase-2-clinical-trials","title":{"rendered":"VINCOV-19, an antidote, and a cure against COVID-19 completes Phase 2 clinical trials"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/XP5gJj0TUoQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>VINS Bioproducts Limited, Hyderabad in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 clinical trials of VINCOV-19, India\u2019s first antidote and cure against SARS-CoV-2 virus.<\/p>\n<p>VINCOV-19 is now ready for market authorisation and for simultaneous Phase 3 clinical trials.<\/p>\n<p>Phase 2 clinical trials were conducted across multiple centres in India and included over 200 patients. The Phase 2 clinical trials also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>VINS Bioproducts Limited, Hyderabad in collaboration with the Centre for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH), announced the successful completion of Phase 2 clinical trials of VINCOV-19, India\u2019s first antidote and cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorisation and for simultaneous Phase 3 clinical trials. Phase [\u2026]<\/p>\n","protected":false},"author":513,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-148104","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/148104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/513"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=148104"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/148104\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=148104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=148104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=148104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}